The company's drug creation platform, based on Anti-angiogenesis-based Artifact Re-targeting Tri-specifics (ART), reduces the side effects of single-target protein therapeutics. This platform enables the development of new drug pipelines through multi-targeting, providing patients with novel drugs and treatments for cancer. Panolos Bioscience focuses on creating bi- and multi-specific biotherapeutics platforms to advance the field of cancer therapy.